Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

Kinetic Muscles Receives Phase 2 Grant

By Drug Discovery Trends Editor | April 5, 2010

Kinetic Muscles Inc., a leading innovator of neurorehabilitation technology, announced it has received a 2-year Phase 2 SBIR grant to study a new treatment for veterans returning from active duty with traumatic brain injury (TBI).

Promising results from a Phase 1 study which combined neuropsychological therapy and digital gaming technology led the DoD to fund this Phase 2 study that will validate effectiveness of the therapy system through clinical testing in VA hospitals.

KMI will collaborate with Emory University, Division of Neuropsychology (Atlanta, GA), the DoD, the VA, and the University of Advancing Technology (Tempe, AZ) which is recognized as one of the foremost ‘gaming’ schools in the nation.

TBI is not only the most prevalent injury affecting today’s soldiers, but is also a major health issue for the general population. The Centers for Disease Control and Prevention (CDC -TBI) report that 1.7 million Americans are affected by traumatic brain injury each year and there are 5.3 million people with permanent TBI-related disability in the United States.

Clinical studies have shown that videogame-based therapies such as those used in KMI’s Hand Mentor can improve cognitive ability, dexterity, memory, thought processing, and reasoning. Therapy interventions incorporating both state-of-the-art gaming technology and cutting edge cognitive and motor rehabilitation strategies have the potential to be cost-effective and engaging particularly for a generation of soldiers who have grown up using videogames for entertainment.

“Treatment of TBI builds upon KMI’s neurotherapy technology platform,” said Ed Koeneman, Chief Operating Officer at KMI and Principal Investigator for the study. “Patients with stroke and TBI experience similar cognitive and movement deficits. KMI technology addresses rehabilitation for both groups through repetitive training of specific tasks.”

David Bolman, Provost of the University of Advancing Technology, added, “We are pleased to work with KMI and Emory University on this important project. This collaboration is representative of the merging of technologies that will shape healthcare in the future.”

Date: April 5, 2010
Source: Kinetic Muscles Inc. 


Filed Under: Drug Discovery

 

Related Articles Read More >

Takeda Pharmaceutical in the Drug Discovery & Development Pharma 50
Takeda’s Takhzyro fares well in pediatric hereditary angioedema study
Novartis in the Pharma 50
Novartis to cut up to 8,000 positions
Gilead Sciences in the Drug Discovery & Development Pharma 50
Gilead resubmits application to FDA for twice-yearly HIV drug lenacapavir
George Floyd mural
How the pandemic and George Floyd made clinical trial diversity a priority

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MASSDEVICE
  • DEVICETALKS
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • MEDTECH 100
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50